Autonomix Medical Secures U.S. Patent For Precision Nerve-Targeted Cancer Treatment Technology

Autonomix Medical has been granted U.S. Patent No. 12,433,670 for technologies designed to sense, map, and selectively target nerves linked to tumors, cancer-related pain, organ function, and other autonomic nervous system disorders. The patent strengthens the company’s intellectual property portfolio as it continues developing precision nerve-targeted therapies using minimally invasive approaches.

The patented technology focuses on catheter-based systems capable of detecting electrophysiological activity in nerves associated with tumors or metastatic cells. By mapping these neural signals, the platform is designed to help physicians identify disease-related nerves and deliver targeted treatment through therapeutic energy or agents while limiting damage to surrounding healthy tissue.

“This patent represents another meaningful expansion of our intellectual property portfolio and further demonstrates the breadth of our proprietary technology platform,” said Brad Hauser, Chief Executive Officer of Autonomix Medical. “Our strategy is to build a comprehensive intellectual property portfolio spanning precision nerve sensing, physiologic assessment and targeted neuromodulation, with potential applications across cancer, organ function and other diseases involving the autonomic nervous system. This latest patent strengthens the foundation supporting that strategy while reinforcing the versatility and long-term potential of our platform.” 

According to the patent, the technology supports multiple functions, including neural signal mapping, selective nerve modulation to manage cancer-related pain, targeted delivery of therapy, and regulation of autonomic nervous system signaling that may influence organ function and the tumor microenvironment. Potential applications extend across several solid tumors, including pancreatic, prostate, breast, colorectal, liver, ovarian, and bone cancers.

The newly issued patent adds to Autonomix’s growing portfolio covering neural sensing, autonomic nervous system assessment, treatment guidance, and transvascular neuromodulation. The company continues to advance its proprietary platform, which is designed to detect neural signals with greater sensitivity than conventional technologies, supporting the development of more precise therapies aimed at improving patient outcomes while minimizing unintended effects.